Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: A preliminary study

Annals of Pharmacotherapy

Volumn 39, Issue 12, 2005, Pages 2003-2008

  Daoud, Yassine ^a   Amin, Ketan G ^b   Mohan, Krishn ^c   Ahmed, A Razzaque ^c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c NEW ENGLAND BAPTIST HOSPITAL   (United States)

^d Center for Blistering Diseases   (United States)

Author keywords

Conventional immunosuppressive therapy, intravenous immunoglobulin therapy; Cost comparison; Mucous membrane pemphigoid

Indexed keywords

IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BULLOUS SKIN DISEASE; CATARACT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; DRUG SAFETY; FATIGUE; FEMALE; FRACTURE; GASTROESOPHAGEAL REFLUX; GLUCOSE INTOLERANCE; HEPATITIS; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; LEUKOPENIA; MALE; MENTAL DISEASE; MOTOR NEUROPATHY; MYOPATHY; OSTEOPOROSIS; PEPTIC ULCER; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

AGED; COHORT STUDIES; DRUG COSTS; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; RETROSPECTIVE STUDIES;

EID: 28544450135     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E595     Document Type: Article

References (27)

1. Tyagi S, Bhol K, Natarajan K, Livir-Rallatos C, Foster CS, Ahmed AR. Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci U S A 1996;93:14714-9.
2. Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000;43:571-91.
3. Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology 1982;89:340-53.
4. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999;106:2136-43.
5. Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol 1983;96:453-9.
6. Foster CS, Neumann R, Tauber J. Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc Ophthalmol 1992;82:223-9.
7. Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991;10:185-95.
8. Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002;102:59-67.
9. Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology 1991;98:858-62.
10. Mondino BJ. Cicatricial pemphigoid and erythema multiforme. Ophthalmology 1990;97:939-52.
11. Drug topics red book. London: Medical Defense Union, 2001.
12. Massachusetts Division of Health Care Finance and Policy: the FY99 PC acute hospital payer, utilization, and discharge data product. www.mass. gov/dhcfp/pages/dhcfp_59.htm#anchor2258792 (accessed 2001 Oct 4).
13. United States Bureau of Labor Statistics: economic news release. http://146.142.4.24/cgi-bin/surveymost?cu (accessed 2001 Oct 4).
14. HCIA-Solucient. The guide to the managed care industry. Baltimore: HCIA LLC, 1999:13.
15. Centers for Medicare and Medicaid Services (CMS), Office of the Actuary, National Health Statistics Group, National Health Accounts. www.cms.hhs.gov/ statistics/nhe/historical/chart.asp (accessed 2001 Oct 4).
16. Ahmed AR, Dahl MV. Consensus Statement on the Use of Intravenous Immunoglobulin Therapy in the Treatment of Autoimmune Mucocutaneous Blistering Diseases. Arch Dermatol 2003;139:1051-9.
17. Rosner B. Fundamentals of biostatistics. 5th ed. Pacific Grove, CA: Duxbury Publishing, 2000:275-9.
18. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986;84:527-663.
19. Lee SJ, Li Z, Sherman B, Foster CS. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 1993;34:3522-5.
20. Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol 1979;101:521-34.
21. Kanwar AJ, Dhar S. Factors responsible for death in patients with pemphigus. J Dermatol 1994;21:655-9.
22. Weeks FM, Yee GC, Bartfield A, Wingard JR. True cost of bone marrow transplantation. Am J Med Sci 1997;314:101-12.
23. Welch HG, Larsen EB. Cost effectiveness of bone marrow transplantation in acute non lymphocytic leukemia. N Engl J Med 1989;321:807-12.
24. Centers of Medicare and Medicaid Services, Department of Health and Human Services coverage issues manual. www.cms.hhs.gov/manuals/06_cim/ci35. asp#_1_1%Part%35-30.1%Rev.l38 (accessed 2004 May 29).
25. Prevalence and cost of ESRD therapy. Am J Kidney Dis 1991;18:21-9.
26. Hu RH, Lee PH, Tsai MK, Lee CY. Medical costs between renal transplantation and hemodialysis. Transplant Proc 1998;30:3617-20.
27. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end stage renal disease treatment. Med Decis Making 2002;22:417-30.